SLNCF 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• Presented follow-up data from the Phase 1 SANRECO study at the European Hematology Association (EHA) 2026 Annual Congress in June demonstrating durable efficacy and potential best-in-class profile for divesiran in PV.

• Completed dosing in the Phase 2 SANRECO double-blind, placebo-controlled trial evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients.

• SLN312 (AZD1705): Phase 1 siRNA silencing ANGPTL3 with a competitive profile for dyslipidemia

• Phase 1 results generated under our AstraZeneca collaboration were presented by AstraZeneca during a late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress in May 2026. Results demonstrated a favorable safety profile and dose-dependent, durable reductions in ANGPTL3 p…

• Generated additional preclinical data demonstrating that the effect of SLN365 (GPR146) on lipids was reproduced and not altered by co-treatment with statin or ezetimibe.

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• SANRECO Phase 1 study abstract accepted for poster presentation at the European Hematology Association (EHA) 2026 Annual Congress taking place June 11-14, 2026.

• Divesiran, A Novel GalNac Conjugated SiRNA, Reduces Phlebotomies, Improves Iron Stores and Symptoms in Polycythemia Vera Patients in Sanreco Phase 1 Study

• SANRECO Phase 2 double-blind, placebo-controlled trial evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients is ongoing with topline results on-track for the third quarter of 2026.

• SLN312 (AZD1705): Phase 1 siRNA with a competitive profile for dyslipidemia

• Phase 1 study abstract accepted for late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress taking place May 24-27, 2026.

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• Financial Officer have concluded that, as of June 30, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.

• There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal con…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal cont…